RIAS
KRYS icon

Rachor Investment Advisory Services’s Krystal Biotech KRYS Stock Holding History

Rachor Investment Advisory Services’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8
Closed -$2.07K – 313
2026
Q1 		$2.07K Buy
+8
New +$2.13K ﹤0.01% 256

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Rachor Investment Advisory Services's KRYS Position: Q2 2026 in Review

Rachor Investment Advisory Services sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 8 shares — an estimated $2.07K sold.

Rachor Investment Advisory Services first reported a position in KRYS in Q1 2026 and held it in 1 quarter. The position peaked at $2.07K in Q1 2026. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Rachor Investment Advisory Services reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
  • Rachor Investment Advisory Services sold 8 Krystal Biotech shares in Q2 2026, an estimated $2.07K.
  • Rachor Investment Advisory Services first reported a position in Krystal Biotech in Q1 2026 and held it in 1 quarter.
  • Rachor Investment Advisory Services's Krystal Biotech position peaked at $2.07K in Q1 2026.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Rachor Investment Advisory Services's 13F filing for Q2 2026, filed 16 Jul 2026.